Copyright
©The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Nephrol. Dec 25, 2025; 14(4): 110817
Published online Dec 25, 2025. doi: 10.5527/wjn.v14.i4.110817
Published online Dec 25, 2025. doi: 10.5527/wjn.v14.i4.110817
Comparison of parathormone lowering effects of paricalcitol and calcitriol in hemodialysis patients
Ahmet Murt, Department of Nephrology Clinic, Istanbul University-Cerrahpasa, Cerrahpasa Medical Faculty, Istanbul 34000, Türkiye
Author contributions: Murt A was responsible for the overall conception, design, and execution of the study, including data collection and analysis, literature review, and manuscript preparation.
Institutional review board statement: The study was approved by the Institutional Review Board of Provincial Health Directorate (Approval No. 2020-11-30T14_57_30).
Informed consent statement: All patients signed written informed consent forms and the study was performed according to the rules of Declaration of Helsinki.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
CONSORT 2010 statement: The authors have read the CONSORT 2010 Statement, and the manuscript was prepared and revised according to the CONSORT 2010 Statement.
Data sharing statement:
The data of this study is available from the corresponding author upon a reasonable request.
Open Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Ahmet Murt, Department of Nephrology Clinic, Istanbul University-Cerrahpasa, Cerrahpasa Medical Faculty, No. 53 Kocamustafapaşa Caddesi, Istanbul 34000, Türkiye. ahmet.murt@istanbul.edu.tr
Received: June 16, 2025
Revised: July 20, 2025
Accepted: October 28, 2025
Published online: December 25, 2025
Processing time: 190 Days and 13.2 Hours
Revised: July 20, 2025
Accepted: October 28, 2025
Published online: December 25, 2025
Processing time: 190 Days and 13.2 Hours
Core Tip
Core Tip: Parathormone control has utmost importance for patients undergoing hemodialysis to decrease fracture risk and provide better survival. Although international guidelines recommend keeping parathormone levels between two to nine times of the upper normal limit, new studies provide survival evidence for tighter control. Paricalcitol was found more effective than calcitriol in providing a faster and greater reduction of parathormone. Close monitoring of phosphorus and calcium levels avoided unintended hyperphosphatemia or hypercalcemia with either treatment.